131 related articles for article (PubMed ID: 12925158)
1. Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity.
Thorpe SJ; Fox BJ; Dolman CD; Lawrence J; Thorpe R
Vox Sang; 2003 Aug; 85(2):80-4. PubMed ID: 12925158
[TBL] [Abstract][Full Text] [Related]
2. Anti-Rh D activity of commercial intravenous immunoglobulin preparations.
Turner CE; Thorpe SJ; Brasher MD; Thorpe R
Vox Sang; 1999; 76(1):55-8. PubMed ID: 9933855
[TBL] [Abstract][Full Text] [Related]
3. International collaborative study to evaluate a candidate reference preparation to define an appropriate specified limit of anti-D in intravenous immunoglobulin products.
Thorpe SJ; Fox B; Heath A; Dolman C; Virata ML; Yu MW; Thorpe R
Vox Sang; 2005 May; 88(4):278-87. PubMed ID: 15877651
[TBL] [Abstract][Full Text] [Related]
4. International collaborative study to establish reference preparations to standardise haemagglutination testing for anti-A and anti-B in normal intravenous immunoglobulins by the direct method.
Thorpe SJ; Fox B; Sharp G; Heath AB; Behr-Gross ME; Terao E; Virata-Theimer ML; Yu MW
Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):39-50. PubMed ID: 20223189
[TBL] [Abstract][Full Text] [Related]
5. International collaborative study to evaluate candidate reference reagents to standardize haemagglutination testing for anti-A and anti-B in normal intravenous immunoglobulin products.
Thorpe SJ; Fox B; Sharp G; Heath AB; Behr-Gross ME; Terao E; Virata-Theimer ML; Yu MW
Vox Sang; 2009 Aug; 97(2):160-8. PubMed ID: 19402856
[TBL] [Abstract][Full Text] [Related]
6. International collaborative study to assess candidate reference preparations to control the level of anti-D in IVIG for use in Europe and the United States.
Thorpe SJ; Fox B; Heath A; Behr-Gross ME; Virata ML; Yu MY
Biologicals; 2006 Sep; 34(3):209-12. PubMed ID: 16492398
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature.
Desborough MJ; Miller J; Thorpe SJ; Murphy MF; Misbah SA
Transfus Med; 2014 Aug; 24(4):219-26. PubMed ID: 24164446
[TBL] [Abstract][Full Text] [Related]
8. Anti-A and anti-B haemagglutinin levels in intravenous immunoglobulins: are they on the rise? A comparison of four different analysis methods and six products.
Bellac CL; Polatti D; Hottiger T; Girard P; Sänger M; Gilgen M
Biologicals; 2014 Jan; 42(1):57-64. PubMed ID: 24325871
[TBL] [Abstract][Full Text] [Related]
9. Specifications for anti-A and anti-B in intravenous immunoglobulin: history and rationale.
Thorpe SJ
Transfusion; 2015 Jul; 55 Suppl 2():S80-5. PubMed ID: 26174902
[TBL] [Abstract][Full Text] [Related]
10. International collaborative study to assess new stocks of candidate reference preparations to control the level of anti-D in IVIG.
Thorpe SJ; Virata ML; Fox B; Terao E
Pharmeur Bio Sci Notes; 2024; 2024():76-89. PubMed ID: 38949845
[TBL] [Abstract][Full Text] [Related]
11. Anti-A and anti-B activity in batches of different intravenous immunoglobulin products determined using a direct haemagglutination method.
Thorpe SJ; Fox BJ; Dolman CD; Thorpe R
Biologicals; 2005 Jun; 33(2):111-6. PubMed ID: 15905100
[TBL] [Abstract][Full Text] [Related]
12. Anti-red blood cell antibodies, free light chains, and antiphospholipid antibodies in intravenous immunoglobulin preparations.
Sakem B; Matozan K; Nydegger UE; Weigel G; Griesmacher A; Risch L
Isr Med Assoc J; 2013 Oct; 15(10):617-21. PubMed ID: 24266088
[TBL] [Abstract][Full Text] [Related]
13. Anti-D immunoglobulin-induced prolonged intravascular hemolysis and neutropenia.
Alioglu B; Avci Z; Ozyurek E; Ozbek N
J Pediatr Hematol Oncol; 2007 Sep; 29(9):636-9. PubMed ID: 17805040
[TBL] [Abstract][Full Text] [Related]
14. Hemolysis upon intravenous immunoglobulin transfusion.
Padmore RF
Transfus Apher Sci; 2012 Feb; 46(1):93-6. PubMed ID: 22169381
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Anti-D Immunoglobulins versus Intravenous Immunoglobulins for Immune Thrombocytopenia in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Lioger B; Maillot F; Ternant D; Passot C; Paintaud G; Bejan-Angoulvant T
J Pediatr; 2019 Jan; 204():225-233.e8. PubMed ID: 30314658
[TBL] [Abstract][Full Text] [Related]
16. Hemolytic adverse effects of intravenous immunoglobulin: modeling predicts risk reduction with anti-A/B immunoaffinity chromatography and to a lesser extent with anti-A donor screening.
Mallick R; Hubsch A; Barnes DG
Transfusion; 2018 Dec; 58(12):2752-2756. PubMed ID: 30284263
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects of intravenous immunoglobulin.
Misbah SA; Chapel HM
Drug Saf; 1993 Oct; 9(4):254-62. PubMed ID: 8260119
[TBL] [Abstract][Full Text] [Related]
18. Anti-A and anti-B: what are they and where do they come from?
Branch DR
Transfusion; 2015 Jul; 55 Suppl 2():S74-9. PubMed ID: 26174901
[TBL] [Abstract][Full Text] [Related]
19. Haemolysis after treatment with intravenous immunoglobulin due to anti-A.
Morgan S; Sorensen P; Vercellotti G; Zantek ND
Transfus Med; 2011 Aug; 21(4):267-70. PubMed ID: 21605202
[TBL] [Abstract][Full Text] [Related]
20. Anti-SSA antibodies are present in immunoglobulin preparations.
van der Molen RG; Hamann D; Jacobs JF; van der Meer A; de Jong J; Kramer C; Strengers PF; van der Meer JW
Transfusion; 2015 Apr; 55(4):832-7. PubMed ID: 25394209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
